STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million

Article excerpt

A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing. Ollin Biosciences is about to begin a Phase 3 trial of a treatment for both diabetic macular edema and wet age-related macular degeneration. The conditions affect millions of Americans and can lead to vision loss.  Ahead of the trial, Ollin told STAT it had raised the Series B funding from an assortment of established biotech investors, a pension fund, and even crossover investors, a breed of private investors who will take a stake in a company shortly before it moves over to the stock market. TCGX and ARCH Venture Partners co-led the funding round, which was one of the largest Series B rounds for a biotech company in the last two years.  Continue to STAT+ to re